Vioxx rofecoxib: Phase IV data; marketed to treat osteoarthritis and pain

Data from MRK's 8,000-patient VIGOR study showed a significant reduction in serious

Read the full 120 word article

How to gain access

Continue reading with a
two-week free trial.